Regeneron Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients
- Conditions
- Advanced Non-small Cell Lung Cancer
- Interventions
- Other: Platinum-doublet chemotherapy
- First Posted Date
- 2024-02-21
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 1000
- Registration Number
- NCT06269133
- Locations
- 🇺🇸
Regeneron Research Facility, Tarrytown, New York, United States
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
- Conditions
- Melanoma
- Interventions
- First Posted Date
- 2024-02-07
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 560
- Registration Number
- NCT06246916
- Locations
- 🇺🇸
Ironwood Cancer & Research Centers, Chandler, Arizona, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Arizona Oncology Associates, Tucson, Arizona, United States
REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction
- First Posted Date
- 2024-02-01
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 391
- Registration Number
- NCT06237309
- Locations
- 🇪🇸
Hospital Universitario Virgen Macarena Unidad Coronaria 1 planta, Sevilla, Spain
🇵🇱Wojewodzki Szpital Zespolony - Ludwik Rydygier Provincial Hospital, Torun, Kuyavian-Pomeranian, Poland
🇵🇱UCK Medical University of Warsaw, Warszawa, Mazowieckie, Poland
A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma
- Conditions
- B-Cell Non-Hodgkin Lymphoma (B-NHL)
- Interventions
- First Posted Date
- 2024-01-30
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 216
- Registration Number
- NCT06230224
- Locations
- 🇨🇳
Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
🇪🇸Hospital Universitario Infanta Leonor, Madrid, Spain
🇪🇸Hospital Universitario Ramon y Cajal, Madrid, Spain
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
- Conditions
- Melanoma
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 150
- Registration Number
- NCT06190951
- Locations
- 🇺🇸
UC San Diego, La Jolla, California, United States
🇺🇸USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Hoag Family Cancer Institute, Newport Beach, California, United States
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery
- Conditions
- Resectable Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-12-07
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 180
- Registration Number
- NCT06161441
- Locations
- 🇷🇴
Medisprof Cancer Center, Cluj-Napoca, Cluj, Romania
🇲🇾Hospital Kuala Lumpur, Kuala Lumpur, Wilayah Persekutuan, Malaysia
🇲🇾Hospital Umum Sarawak, Kuching, Malaysia
A Trial to Learn if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
- Conditions
- Marginal Zone Lymphoma (MZL)Relapsed/Refractory Follicular Lymphoma
- Interventions
- First Posted Date
- 2023-11-28
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 470
- Registration Number
- NCT06149286
- Locations
- 🇦🇹
Klinikum Wels Grieskirchen, Wels, Austria
🇧🇪Institut Jules Bordet, Brussels, Belgium
🇺🇸David Geffen School of Medicine at UCLA, Los Angeles, California, United States
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
- Conditions
- Monoclonal Gammopathy of Undetermined Significance (MGUS)Smoldering Multiple Myeloma (SMM)
- Interventions
- First Posted Date
- 2023-11-20
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 104
- Registration Number
- NCT06140524
- Locations
- 🇪🇸
Universitaru Hospital La Princesa, Madrid, Spain
🇺🇸Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Study to See How Safe and Tolerable Different Doses of REGN13335 Are When Administered Intravenously (IV) or Subcutaneously (SC) to Healthy Adult Participants
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 56
- Registration Number
- NCT06137482
- Locations
- 🇳🇿
New Zealand Clinical Research, Christchurch, Canterbury, New Zealand
Expanded Access Use of Cemiplimab in Patients With Solid Tumors
- First Posted Date
- 2023-11-15
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Regeneron Pharmaceuticals
- Registration Number
- NCT06132191